Guggenheim upgraded Health Catalyst to Buy from Neutral with a $14 price target. The analyst thinks the TEMS deals that slipped into 2024 are close to deal signing following a conversation with the company and says management is incrementally positive on DOS pipeline commentary. Health Catalyst is trading at a material discount relative to reasonable growth expectations, creating a favorable risk/reward profile, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HCAT:
- Health Catalyst price target raised to $17 from $12 at Piper Sandler
- ‘Profitability Is the Key’: Barclays Says These 3 Health Tech Stocks Are Poised for Growth
- Health Catalyst upgraded to Outperform at Evercore ISI on IT demand inflection
- Barclays starts healthcare technology, distribution with Neutral view
- Health Catalyst upgraded to Outperform from In Line at Evercore ISI
